Advertisement

The Diabetic Phenotype in HNF4A Mutation Carriers Is Moderated By the Expression of HNF4A Isoforms From the P1 Promoter During Fetal Development

  1. Lorna W. Harries1,
  2. Jonathan M. Locke1,
  3. Beverley Shields1,
  4. Neil A. Hanley2,
  5. Karen Piper Hanley2,
  6. Anna Steele1,
  7. Pål R. Njølstad34,
  8. Sian Ellard1 and
  9. Andrew T. Hattersley1
  1. 1Institute of Biomedical and Clinical Sciences, Peninsula Medical School, Exeter, U.K
  2. 2Centre for Human Development, Stem Cells & Regeneration, Human Genetics Division, University of Southampton, Southampton, U.K
  3. 3Department of Clinical Medicine, University of Bergen, Bergen, Norway
  4. 4Department of Paediatrics, Haukeland University Hospital, Bergen, Norway
  1. Corresponding author: L.W. Harries, Institute of Biomedical and Clinical Sciences, Peninsula Medical School, Barrack Road, Exeter, U.K. E-mail: l.w.harries{at}exeter.ac.uk

Abstract

OBJECTIVE—Mutations in the alternatively spliced HNF4A gene cause maturity-onset diabetes of the young (MODY). We characterized the spatial and developmental expression patterns of HNF4A transcripts in human tissues and investigated their role as potential moderators of the MODY phenotype.

RESEARCH DESIGN AND METHODS—We measured the expression of HNF4A isoforms in human adult tissues and gestationally staged fetal pancreas by isoform-specific real-time PCR. The correlation between mutation position and age of diagnosis or age-related penetrance was assessed in a cohort of 190 patients with HNF4A mutations.

RESULTS—HNF4A was expressed exclusively from the P2 promoter in adult pancreas, but from 9 weeks until at least 26 weeks after conception, up to 23% of expression in fetal pancreas was of P1 origin. HNF4A4–6 transcripts were not detected in any tissue. In whole pancreas, HNF4A9 expression was greater than in islets isolated from the endocrine pancreas (relative level 22 vs. 7%). Patients with mutations in exons 9 and 10 (absent from HNF4A3, HNF4A6, and HNF4A9 isoforms) developed diabetes later than those with mutations in exons 2–8, where all isoforms were affected (40 vs. 24 years; P = 0.029). Exon 9/10 mutations were also associated with a reduced age-related penetrance (53 vs. 10% without diabetes at age 55 years; P < 0.00001).

CONCLUSIONS—We conclude that isoforms derived from the HNF4A P1 promoter are expressed in human fetal, but not adult, pancreas, and that their presence during pancreatic development may moderate the diabetic phenotype in individuals with mutations in the HNF4A gene.

Footnotes

  • Published ahead of print at http://diabetes.diabetesjournals.org on 20 March 2008. DOI: 10.2337/db07-1742.

  • Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db07-1742.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • See accompanying commentary, p. 1461.

    • Accepted March 17, 2008.
    • Received December 12, 2007.
| Table of Contents

This Article

  1. Diabetes vol. 57 no. 6 1745-1752
  1. Online-Only Appendix
  2. All Versions of this Article:
    1. db07-1742v1
    2. 57/6/1745 most recent
Advertisement